Articles producció científica> Bioquímica i Biotecnologia

Association of tryptophan metabolites with incident type 2 diabetes in the PREDIMED trial: A case–cohort study

  • Identification data

    Identifier: imarina:3992546
    Authors:
    Yu EPapandreou CRuiz-Canela MGuasch-Ferre MClish CBDennis CLiang LCorella DFitó MRazquin CLapetra JEstruch RRos ECofán MArós FToledo ESerra-Majem LSorlí JVHu FBMartinez-Gonzalez MASalas-Salvado J
    Abstract:
    © 2018 American Association for Clinical Chemistry. BACKGROUND: Metabolites of the tryptophan– kynurenine pathway (i.e., tryptophan, kynurenine, kynurenic acid, quinolinic acid, 3-hydroxyanthranilic) may be associated with diabetes development. Using a case– cohort design nested in the Prevención con Dieta Mediterránea (PREDIMED) study, we studied the associations of baseline and 1-year changes of these metabolites with incident type 2 diabetes (T2D). METHODS: Plasma metabolite concentrations were quantified via LC-MS for n 641 in a randomly selected subcohort and 251 incident cases diagnosed during 3.8 years of median follow-up. Weighted Cox models adjusted for age, sex, body mass index, and other T2D risk factors were used. RESULTS: Baseline tryptophan was associated with higher risk of incident T2D (hazard ratio 1.29; 95% CI, 1.04 –1.61 per SD). Positive changes in quinolinic acid from baseline to 1 year were associated with a higher risk of T2D (hazard ratio 1.39; 95% CI, 1.09 –1.77 per SD). Baseline tryptophan and kynurenic acid were directly associated with changes in homeostatic model assessment for insulin resistance (HOMA-IR) from baseline to 1 year. Concurrent changes in kynurenine, quinolinic acid, 3-hydroxyanthranilic acid, and kynurenine/tryptophan ratio were associated with baseline-to-1-year changes in HOMA-IR. CONCLUSIONS: Baseline tryptophan and 1-year increases in quinolinic acid were positively associated with incident T2D. Baseline and 1-year changes in tryptophan metabolites predicted changes in HOMA-IR. Tryptophan levels may initially increase and then deplete as diabetes progresses in severity.
  • Others:

    Author, as appears in the article.: Yu E; Papandreou C; Ruiz-Canela M; Guasch-Ferre M; Clish CB; Dennis C; Liang L; Corella D; Fitó M; Razquin C; Lapetra J; Estruch R; Ros E; Cofán M; Arós F; Toledo E; Serra-Majem L; Sorlí JV; Hu FB; Martinez-Gonzalez MA; Salas-Salvado J
    Department: Bioquímica i Biotecnologia
    URV's Author/s: Salas Salvadó, Jorge
    Keywords: @infoAeu @residentesaeu @uroweb Etiqueta «#» Hashtag
    Abstract: © 2018 American Association for Clinical Chemistry. BACKGROUND: Metabolites of the tryptophan– kynurenine pathway (i.e., tryptophan, kynurenine, kynurenic acid, quinolinic acid, 3-hydroxyanthranilic) may be associated with diabetes development. Using a case– cohort design nested in the Prevención con Dieta Mediterránea (PREDIMED) study, we studied the associations of baseline and 1-year changes of these metabolites with incident type 2 diabetes (T2D). METHODS: Plasma metabolite concentrations were quantified via LC-MS for n 641 in a randomly selected subcohort and 251 incident cases diagnosed during 3.8 years of median follow-up. Weighted Cox models adjusted for age, sex, body mass index, and other T2D risk factors were used. RESULTS: Baseline tryptophan was associated with higher risk of incident T2D (hazard ratio 1.29; 95% CI, 1.04 –1.61 per SD). Positive changes in quinolinic acid from baseline to 1 year were associated with a higher risk of T2D (hazard ratio 1.39; 95% CI, 1.09 –1.77 per SD). Baseline tryptophan and kynurenic acid were directly associated with changes in homeostatic model assessment for insulin resistance (HOMA-IR) from baseline to 1 year. Concurrent changes in kynurenine, quinolinic acid, 3-hydroxyanthranilic acid, and kynurenine/tryptophan ratio were associated with baseline-to-1-year changes in HOMA-IR. CONCLUSIONS: Baseline tryptophan and 1-year increases in quinolinic acid were positively associated with incident T2D. Baseline and 1-year changes in tryptophan metabolites predicted changes in HOMA-IR. Tryptophan levels may initially increase and then deplete as diabetes progresses in severity.
    Thematic Areas: Odontología Medicine (miscellaneous) Medicine (all) Medicina iii Medicina ii Medicina i Medical laboratory technology General medicine Farmacia Clinical biochemistry Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Biochemistry (medical)
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 00099147
    Author's mail: jordi.salas@urv.cat
    Author identifier: 0000-0003-2700-7459
    Record's date: 2024-09-07
    Papper version: info:eu-repo/semantics/acceptedVersion
    Link to the original source: https://academic.oup.com/clinchem/article/64/8/1211/5608820
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Clinical Chemistry. 64 (8): 1211-1220
    APA: Yu E; Papandreou C; Ruiz-Canela M; Guasch-Ferre M; Clish CB; Dennis C; Liang L; Corella D; Fitó M; Razquin C; Lapetra J; Estruch R; Ros E; Cofán M; Ar (2018). Association of tryptophan metabolites with incident type 2 diabetes in the PREDIMED trial: A case–cohort study. Clinical Chemistry, 64(8), 1211-1220. DOI: 10.1373/clinchem.2018.288720
    Article's DOI: 10.1373/clinchem.2018.288720
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2018
    Publication Type: Journal Publications
  • Keywords:

    Biochemistry (Medical),Clinical Biochemistry,Medical Laboratory Technology,Medicine (Miscellaneous)
    Odontología
    Medicine (miscellaneous)
    Medicine (all)
    Medicina iii
    Medicina ii
    Medicina i
    Medical laboratory technology
    General medicine
    Farmacia
    Clinical biochemistry
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Biotecnología
    Biochemistry (medical)
  • Documents:

  • Cerca a google

    Search to google scholar